))
Going Beyond Today’s Assessments to Confirm COPD, Are Biomarkers Key?
Manage episode 456333450 series 3381434
Вміст надано ReachMD. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією ReachMD або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.
CME credits: 0.50
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/going-beyond-todays-assessments-to-confirm-copd-are-biomarkers-key/27035/
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
…
continue reading
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/going-beyond-todays-assessments-to-confirm-copd-are-biomarkers-key/27035/
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
461 епізодів
Поширити
